Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer.
- DOI
- 10.1007/s40487-025-00350-6
- Published
- 2025 Sep
- Container
- Oncology and therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40487-025-00350-6,
title = {Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer.},
author = {Garassino MC and Cheng Y and Rodriguez-Abreu D and Novello S and Mazieres J and Robinson AG and Powell SF and Halmos B and Gray JE and Wang M and Chen C and Yang J and Souza F and Schwarzenberger P and Paz-Ares L},
year = {2025},
journal = {Oncology and therapy},
doi = {10.1007/s40487-025-00350-6},
url = {https://doi.org/10.1007/s40487-025-00350-6}
}RIS
TY - JOUR TI - Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer. AU - Garassino MC AU - Cheng Y AU - Rodriguez-Abreu D AU - Novello S AU - Mazieres J AU - Robinson AG AU - Powell SF AU - Halmos B AU - Gray JE AU - Wang M AU - Chen C AU - Yang J AU - Souza F AU - Schwarzenberger P AU - Paz-Ares L PY - 2025 JO - Oncology and therapy DO - 10.1007/s40487-025-00350-6 UR - https://doi.org/10.1007/s40487-025-00350-6 ER -
APA
MC, G., Y, C., D, R., S, N., J, M., AG, R., SF, P., B, H., JE, G., M, W., C, C., J, Y., F, S., P, S., & L, P. (2025). Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer.. Oncology and therapy. https://doi.org/10.1007/s40487-025-00350-6
Source records
- pubmed · retrieved 2026-09-26T18:43:04.799Z
- europe-pmc · retrieved 2026-09-26T18:43:04.815Z
- doaj · retrieved 2026-09-26T18:43:04.822Z